“Maintenance of Response with Certolizumab Pegol for the Treatment of Chronic Plaque Psoriasis: 48-Week Results from Two Ongoing Phase 3, Multicenter, Randomized, Placebo-Controlled Studies (CIMPASI-1 and CIMPASI-2)” (2017) SKIN The Journal of Cutaneous Medicine, 1(3.1), p. s23. doi:10.25251/skin.1.supp.22.